Mitochondrial Disorders After 12 Months of Human Immunodeficiency Virus Type 1 Preexposure Prophylaxis Based on Tenofovir Disoproxil Fumarate Plus Emtricitabine in Healthy Adults

Simple item page
dc.contributor.authorEsperanza Muñoz‐Muela
dc.contributor.authorMarta Mejías-Trueba
dc.contributor.authorAna Serna‐Gallego
dc.contributor.authorAbraham Saborido-Alconchel
dc.contributor.authorSusana Fernández-Pérez
dc.contributor.authorMarta Herrero
dc.contributor.authorCésar Sotomayor
dc.contributor.authorAlicia Gutiérrez‐Valencia
dc.contributor.authorMaría Trujillo‐Rodríguez
dc.contributor.authorLuís F. López‐Cortés
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:00:51Z
dc.date.available2026-03-22T14:00:51Z
dc.date.issued2025
dc.descriptionCitaciones: 4
dc.description.abstractTDF/FTC-based PrEP induces mitochondrial toxicity in healthy subjects after 12 months of treatment, negatively affecting mitochondrial function and morphology.
dc.identifier.doi10.1093/infdis/jiaf156
dc.identifier.urihttps://doi.org/10.1093/infdis/jiaf156
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/44037
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofThe Journal of Infectious Diseases
dc.sourceInstituto de Biomedicina de Sevilla
dc.subjectEmtricitabine
dc.subjectTenofovir
dc.subjectPre-exposure prophylaxis
dc.subjectHuman immunodeficiency virus (HIV)
dc.subjectMedicine
dc.subjectVirology
dc.titleMitochondrial Disorders After 12 Months of Human Immunodeficiency Virus Type 1 Preexposure Prophylaxis Based on Tenofovir Disoproxil Fumarate Plus Emtricitabine in Healthy Adults
dc.typearticle

Files

Collections

Artículo Científico Publicado